<?xml version="1.0" encoding="UTF-8"?>
<p>The SARS‐CoV‐2 genome is very close to that of the severe acute respiratory syndrome coronavirus (SARS‐CoV) [
 <xref rid="feb213806-bib-0001" ref-type="ref">1</xref>]. From the past efforts to cure RNA virus infections, including the experiences from the SARS and Middle East respiratory syndrome (MERS) epidemics, several potential target proteins and drugs have been proposed [
 <xref rid="feb213806-bib-0012" ref-type="ref">12</xref>, 
 <xref rid="feb213806-bib-0013" ref-type="ref">13</xref>]. The 3C‐like (main) proteinase, surface glycoprotein [
 <xref rid="feb213806-bib-0008" ref-type="ref">8</xref>], and RNA‐dependent RNA polymerase are thought to be the most promising targets for anti‐COVID‐19 therapeutics. For example, the anti‐HIV drug lopinavir/ritonavir, which has been proposed to treat SARS [
 <xref rid="feb213806-bib-0014" ref-type="ref">14</xref>, 
 <xref rid="feb213806-bib-0015" ref-type="ref">15</xref>], is expected to be effective toward SARS‐CoV‐2 3C‐like proteinase [
 <xref rid="feb213806-bib-0016" ref-type="ref">16</xref>, 
 <xref rid="feb213806-bib-0017" ref-type="ref">17</xref>]. Additionally, the antiviral drug remdesivir is expected to target the RNA‐dependent RNA polymerase [
 <xref rid="feb213806-bib-0018" ref-type="ref">18</xref>].
</p>
